NAGE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Niagen Bioscience Inc (NAGE) is not a strong buy at this moment for a beginner investor with a long-term focus. While the company has shown strong financial growth in the latest quarter, the technical indicators suggest a bearish trend, and there are no significant positive trading signals or catalysts to justify immediate action. Holding off until after the upcoming earnings report on March 4, 2026, may provide better clarity on the company's future performance.
The technical indicators for NAGE are bearish. The MACD is below zero and negatively contracting, the RSI is at 17.973 indicating an oversold condition, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 5.024), with resistance at R1: 5.982.
The company has shown strong financial performance in Q3 2025, with revenue up 32.86% YoY, net income up 143.77% YoY, and EPS up 150.00% YoY. Additionally, the company is a leader in NAD+ science and healthy aging research, which is a growing market.
Technical indicators are bearish, and there are no significant hedge fund or insider trading trends. The stock has a 60% chance of declining by 0.9% in the next day and a 14.94% chance of increasing in the next month, which suggests uncertainty in the short term. No recent congress trading data or influential figure activity is available.
In Q3 2025, Niagen Bioscience reported strong financial growth: Revenue increased by 32.86% YoY to $33,986,000, net income increased by 143.77% YoY to $4,578,000, EPS increased by 150% YoY to 0.05, and gross margin improved to 64.52%, up 1.62% YoY.
No recent analyst rating or price target changes are available for NAGE.
